英特格拉生命科学 IART 深 沪
已收盘 02-06 16:00:00 美东时间
11.26
+0.380
+3.49%
华盛通- 最 高11.28
- 今 开10.89
- 成交量 68.69万股
- 最 低 10.785
- 昨 收 10.88
- 总市值 8.77亿
- 52周最高 25.45
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 10.65
- 委 比 -99.83%
- 总股本 7789.21万
- 历史最高 77.40
- 量 比 0.95
- 振 幅 4.55%
- 历史最低 8.36
- 每 手 1
- 风险率 3.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Says Integra Lifesciences Identified Packaging Failures Related To MediHoney Wound & Burn Products That Could Lead To A Breach In The Sterile Barrier; Integra Lifesciences Identified Production And Process Control Issues For Certain CVS Wound Gel Products; As Of December 19, 2025, Integra Lifesciences Has Reported 11 Serious Injuries Related To MediHoney Wound And Burn Products, Has Reported 3 Serious Injuries Related To CVS Wound Gel Products; Reported No Deaths Associated
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-wound-and-burn-dressing-issue-integra-lifesciences
01-23 01:44
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast will be available on the company's investor relations website. Integra, a global medical technology leader, aims to restore patients' lives through innovative care solutions. For more information, visit their website or con...
01-05 21:31
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025. A live webcast will be available on the company's investor relations website.
2025-12-01 21:30
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
Integra LifeSciences commends CMS for new Medicare rules expanding access to its four skin substitute platforms, benefiting wound reconstruction. The products, including Integra® matrices, PriMatrix® and Cytal® and AmnioExcel®, are supported by robust clinical evidence and modernized reimbursement structures, enhancing patient care across care settings.
2025-11-25 13:30
Integra LifeSciences Gets U.S. FDA's Clearance For Use Of Its CUSA Clarity Ultrasonic Surgical Aspirator System For Cardiac Surgeries
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA® Clarity Ultrasonic Surgical Aspirator System
2025-11-12 05:16
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
2025-11-03 20:20
JP Morgan Maintains Underweight on Integra Lifesciences, Raises Price Target to $13
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and raises the price target from $12 to $13.
2025-11-01 02:40
Integra Lifesciences Narrows FY2025 Adj EPS Guidance from $2.19-$2.29 to $2.19-$2.24 vs $2.21 Est; Lowers FY2025 Sales Guidance from $1.655B-$1.680B to $1.620B-$1.640B vs $1.669B Est
Integra Lifesciences (NASDAQ:IART) narrows FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.24 vs $2.21 analyst estimate. Lowers FY2025 sales outlook from $1.655 billion-$1.680 billion to $1.620 billion-$1.640
2025-10-30 18:01
Integra LifeSciences Advances with MIRROR Registry Study on Hematoma Evacuation
Integra Lifesciences (($IART)) announced an update on their ongoing clinical st...
2025-10-28 03:20
